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1. Introduction 
In the United Kingdom, oesophageal cancer ranks as the ninth most common cancer with 
a rising incidence of 13 per 100,000 head of population. Some two-thirds of all 
oesophageal lesions are adenocarcinomas, the rest are squamous cell carcinomas. The 
incidence of stomach cancer is similar but a decline has been registered over the past two 
decades. For both conditions the age at presentation is 60 years or more in over two-thirds 
of patients. Tumours of the oesophago-gastric junction have received detailed attention 
over the past years. This is in part because surgical excision through a single operative 
field may not be possible. Moreover, for this subset of lesions, a rising incidence and 
worse survival have been registered. 
Oesophago-gastric malignancies carry a poor prognosis especially when diagnosed at an 
advanced stage outside screening programmes. In Western countries, this is reflected as 
overall five year-survival rates ranging from 5 to below 20%. Over the years, treatment 
has evolved into a multi-modality strategy which is best formulated and overseen in a 
multidisciplinary setting. The treatment of an individual patient will depend on accurate 
and reliable tumour staging, assessment of the patient’s fitness for radical surgical and/or 
oncological treatment, the level of expertise available locally and, of course, the patient’s 
informed decisions. In a typical surgical unit in the United Kingdom, resection rates will 
not usually surpass 20%.  
After radical surgery with curative intent the median disease free survival is of the order of 
two years with 50% of cases developing metastases and/or recurrence in the first year. These 
disheartening figures offer the rationale for the addition of further oncological treatment to 
radical surgery. Neoadjuvant chemotherapy and/or radiotherapy is administered before 
surgery with the aim of shrinking the primary tumour and theoretically ablating micro-
metastases and reducing the risk of haematogenous and lymphatic dissemination. This 
treatment, however, has the potential for toxicity and complications and must be used 
carefully in patients with co-morbidity. There are concerns that pre-operative treatment may 
influence the patient’s ability to withstand the surgical insult and the percentage of patients 
who are fit enough to complete post-surgical treatment regimens is also diminished.  
This chapter will review the main influential randomised trials employing neoadjuvant 
treatment for these cancers. It will also comment on the other randomised and non-
randomised series published in the literature focusing on the effect of treatment on 
resectability, peri-operative morbidity and mortality, resection specimen pathological 
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stage and completeness of excision and longer-term outcomes. Finally, future prospects 
will be explored. 
2. Neoadjuvant radiotherapy for oesophageal cancer 
Preoperative radiotherapy in oesophageal cancer patients aims to reduce tumour size, 
decrease the extent of localised microscopic residual disease and lower the risk of tumour 
dissemination at the time of surgery. The first published study suggesting that such 
treatment may improve survival for this group of patients was by Kakyama et al in 1967. 
The study reported a 5 year survival rate of 37.5% for the group receiving preoperative 
radiotherapy compared with 19.1% 5 year survival rate in the surgery alone arm. The 
criticisms of the study are that it was retrospective with no statistical analysis of the data.  
During the 1980’s and early 1990’s five randomised controlled trials were published 
comparing neoadjuvant radiotherapy and surgery alone (Launois et al 1981, Gignoux et al 
1987, Wang et al 1989, Arnott et al 1992 and Nygaard et al 1992). All these studies except for 
Arnott et al were restricted to treating squamous cell carcinoma. Radiation doses ranged 
from 20Gy to 40Gy and were given over a period of eight to twenty eight days. A summary 
of the five trials is shown in Table 1. 
 
Study 
Tumour 
histology 
Treatment n 
Percentage of patients 
alive at 5 years 
Launois  
et al 1981 
SCC 
Surgery alone 
 
Pre-op radiotherapy + 
Surgery 
57 
 
67 
11.5 
 
9.5 
Gignoux  
et al 1987 
SCC 
Surgery alone 
 
Pre-op radiotherapy + 
Surgery 
102 
 
106 
11 
 
10 
Wang et al 
1989 
SCC 
Surgery alone 
 
Pre-op radiotherapy + 
Surgery 
102 
 
104 
30 
 
35 
Arnott et al 
1992 
SCC & Adeno
Surgery alone 
 
Pre-op radiotherapy + 
Surgery 
86 
 
90 
17 
 
9 
Nygaard  
et al 1992 
SCC 
Surgery alone 
 
 Pre-op radiotherapy + 
Surgery 
41 
 
48 
9 
 
21 
 
Table 1. A summary of neoadjuvant radiotherapy studies. SCC – squamous cell carcinoma. 
Adeno – adenocarcinoma. 
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None of the trials proved any significant improvement in 5 year survival. However, 
Nygaard et al 1992 did report 3-year survival rates of 20% in those patients receiving 
preoperative radiotherapy compared to 5% in the surgery alone arm. This improved 
survival was only achieved after pooling data from the radiotherapy group with patients 
receiving preoperative chemo-radiotherapy and did not prove to be statistically 
significant. 
Each of the five trials mentioned contained relatively small numbers of patients. Therefore 
in order to investigate any small benefit afforded by preoperative radiotherapy, data from 
all 1147 patients were used in a meta-analysis published by Arnott et al 1998. This study 
again showed there was no clear evidence that preoperative radiotherapy improves the 
survival of patients with potentially resectable oesophageal cancer [hazard ratio (HR) 0.89; 
(95% CI 0.78 –1.01); p=0.062].  
To date there have been no new studies published relating to neoadjuvant radiotherapy 
(Cochrane Review, Arnott et al 2010).  
3. Neoadjuvant chemotherapy for oesophageal and gastric cancer 
Chemotherapy aims to downstage tumours and remove distant micro metastasises. There 
have been many randomised controlled trials comparing overall survival of oesophageal 
cancer patients receiving neoadjuvant chemotherapy followed by surgery with surgery 
alone (Roth et al 1988, Nygaard et al 1992, Schlag et al 1992, Maipang 1994, Law 1997, Kelsen 
1998, Acona 2001 and The UK Medical Research Council (MRC) trial 2002. The two largest 
of these studies are by Kelsen et al 1998 and the MRC trial of 2002. 
Kelsen et al enrolled 440 patients with resectable oesophageal cancer that included 
squamous cell carcinoma, adenocarcinomas and undifferentiated tumours. The patients 
were randomised into two groups. 
The surgery alone group numbered 227 patients who had primary surgery. The 
chemotherapy arm of the trial consisted of 213 patients. Both underwent the same surgical 
procedure. Surgical mortality was similar in each group, 10% in the chemotherapy arm and 
13% in surgery alone group. 
The  patients in the chemotherapy arm received three cycles of cisplatin and fluorouracil 
before surgery. 71% of patients completed all three cycles. 7% of patients showed a complete 
clinical regression while 12% achieved a partial regression. Complete responses (T0N0M0) 
were found in 2.5% of patients.  
Following chemotherapy 133 patients went on to have a R0 resection. This sub group was 
due to receive two post-operative cycles of chemotherapy, however, only 32% completed 
both courses due to patient or physician choice. 
Overall median survival in the surgery alone group was 16.1 months compared to 14.9 
months in the chemotherapy group (p=0.53). Two year survival was 37% and 35% 
respectively (p=0.74). There was no difference in outcome between patients with 
adenocarcinoma and squamous cell carcinoma. Among patients whose resection was 
curative, there was no significant difference in survival between those who did and those 
who did not undergo chemotherapy (median survival, 27.4 and 25 months, respectively). 
Kelsen et al concluded that neoadjuvant chemotherapy did not improve survival in 
oesophageal cancer. It must be noted that the operative mortality in this study is higher than 
would be deemed acceptable at present (less than 5%). 
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Kelsen et al 2007 published an update on their 1998 paper in which they looked at the 
longer term survival of the same group of patients. This again showed no difference in 
overall survival between patients receiving preoperative chemotherapy compared to 
those receiving surgery alone although patients with objective tumour regression after 
preoperative chemotherapy did have an improved survival. The paper also evaluated 
failure patterns on the basis of completeness of resection, concluding that only R0 
resection results in substantial long term survival irrespective of whether neoadjuvant 
chemotherapy is given. 
Like Kelsen et al the MRC study was a multi-centre trial recruiting patients suffering from 
either adenocarcinoma or squamous cell carcinoma of the oesophagus. 802 patients took 
part and were randomised into two groups, surgery alone n=402 and preoperative 
chemotherapy plus surgery n=400. Two cycles of chemotherapy were given using 
cisplatin and fluorouracil. Unlike Kelsen’s study, the MRC trial allowed clinicians to give 
patients preoperative radiotherapy (25-32.5Gy). Nine percent of patients in both groups 
received radiotherapy. 
Of the 400 patients assigned to the chemotherapy arm, 372 received chemotherapy, 350 
completed two cycles while 22 patients only completed one. Pathological data from the 
resected specimens showed that patients who received preoperative chemotherapy had 
smaller tumours (p=0.0001) that extended less frequently into surrounding tissue and 
showed less lymph node involvement than tumours in the surgery alone group. Nodes at 
any site were involved in 195 (58%) of the chemotherapy group and 216 (68%) of the surgery 
alone patients (p=0.009).  
Median survival in the chemotherapy group was 16.8 months compared with 13.3 months in 
the surgery alone group. Two year survival rates were 43% compared with 34%, 
respectively. There was no evidence to suggest that the effect of chemotherapy varied in 
accordance with histology. The MRC trial concluded that overall survival was better in the 
neoadjuvant chemotherapy group than the surgery alone group (HR 0.79; 95% CI 0.67–0.93; 
p=0.004) with an estimated reduction in risk of death of 21%.  
Critics of the MRC study suggest that the inclusion of patients receiving preoperative 
radiotherapy as well as neoadjuvant chemotherapy may be the cause for the improved 
survival in the chemotherapy group. However, the estimate of treatment effect on overall 
survival was not altered by removal of those patients from the analysis who received 
preoperative radiotherapy; hazard ratio for the 728 patients (364 CS, 364 S) who did not 
receive radiotherapy was 0.78 (95% CI 0.66–0.93; p=0.005). In the chemotherapy group 
compared with the surgery alone group, more patients were alive without residual or 
recurrent disease (p<0.0001) 
In 2009 the long term results of the MRC 2002 trial were published. This paper confirmed 
that survival benefit was maintained in the chemotherapy group with a hazard ratio of 0.84 
(95% CI, 0.72 to 0.98; p =0 .03) which in absolute terms is a 5-year survival of 23.0% for 
chemotherapy group compared with 17.1% for surgery alone patients. The study also 
showed that the treatment effect is consistent in both adenocarcinoma and squamous cell 
carcinoma (Allum et al 2009).  
As well as the MRC 2002 and Kelsen study six other smaller randomised control trials have 
compared survival between oesophageal cancer patients receiving surgery alone or 
neoadjuvant chemotherapy plus surgery. These additional studies are listed in Table 2 and 
all contain small numbers of participants.  
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Study CS, number of patients S, number of patients 
Roth et al 1988 19 20 
Nygaard et al 1992 56 25 
Schlag et al 1992 22 24 
Maipang et al 1994 24 22 
Law et al 1997 74 73 
Kelsen 1998 233 234 
Ancona et al 01 48 48 
MRC 02 400 402 
Total 876 848 
Table 2. Randomised control trials comparing surgery alone (S) vs neoadjuvant 
chemotherapy plus surgery (CS) for the treatment of resectable oesophageal cancer. 
Combining the data from all eight studies in a meta-analysis would increase the ability to 
detect an improved survival rate. Furthermore any benefit from preoperative chemotherapy 
relating to the specific histological subtypes could be more effectively elucidated. Gebski et 
al 2007 undertook such a meta-analysis pooling data from 1724 patients. The results showed 
an overall benefit of giving preoperative chemotherapy (HR 0.9; 95% CI 0.81-1.00; p=0.05), 
equating to a survival benefit of 7% at 2 years. The treatment effect of neoadjuvant 
chemotherapy relative to tumour cell type indicated that patients with squamous cell 
carcinoma gained no benefit from preoperative chemotherapy (hazard ratio for mortality 
0.88 (95% CI 0.75-1.03; p=0.12). However, quite the opposite was the case for those with 
adenocarcinoma, who gained a significant benefit from neoadjuvant chemotherapy (hazard 
ratio for mortality 0.78 :95% CI 0.64-0.95: p=0.014). 
Further evidence that neoadjuvant chemotherapy improves survival for patients with 
adenocarcinoma comes in the form of the MRC MAGIC Trial (Cunningham et al 2006) 
which evaluated the survival benefits of giving preoperative epirubicin, cisplatin, and infused 
fluorouracil (ECF) in patients with gastric and oesophagogastric adenocarcenomas.  
In brief, the study recruited 503 patients with resectable adenocarcinoma of the stomach, 
oesophagogastric junction or lower oesophagus. Of the 503 patients approximately 26% had a 
tumour of the lower oesophagus or gastro-oesophageal junction. The patients were 
randomised to receive either preoperative chemotherapy plus surgery  n= 250 or surgery alone  
n=253. Three cycles of ECF were given preoperatively to the chemotherapy group followed by 
three further cycles postoperatively. Only 41.6% of the group completed all six cycles. 
Pathological examination of the resected specimens confirmed significantly smaller tumour 
diameters in the chemotherapy group compared with the surgery alone group (p<0.001). 
The chemotherapy patients also had a higher proportion of T1 and T2 tumours than the 
surgery group (p=0.002) while those patients with gastric cancer showed a significant trend 
to less advanced nodal disease (p=0.01) which suggests tumour shrinkage or ‘down staging’ 
within the chemotherapy group. 
On final analysis the chemotherapy group had a significantly higher likelihood of 
progression-free survival (HR 0.66; 95%CI 0.53 to 0.81; p<0.001) and of overall survival (HR 
0.75; 95% CI 0.60 to 0.93; p = 0.009) which translates into 5 year survival rates of 36.3% for 
the chemotherapy group and 23% for the surgery alone group. Importantly there was no 
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clear evidence of heterogeneity of treatment effect according to the site of the primary 
tumour, age group, sex, or the WHO performance status. These results lead to the trial 
concluding that preoperative ECF chemotherapy improves overall and progression-free 
survival among patients with resectable adenocarcinoma of the stomach, lower esophagus, 
or gastroesophageal junction, as compared with surgery alone. 
Li et al 2010 performed a meta-analysis of 14 trials of neoadjuvant chemotherapy for 
gastric cancer (including of course the MAGIC trial). This study distils some very 
important aspects of the rationale for preoperative treatment and clearly reports some 
conclusions based on large numbers of patients. A total of 2271 patients (1054 in the 
neoadjuvant group and 1217 in the surgery only group) were analysed with a median 
follow-up period of 54 months. Table 3 outlines the main conclusions. 
 
Parameter 
Number of 
studies 
Effect (CS vs S) 
Overall survival at 3 years 12 
48.1% vs 46.9%, favouring CS 
NNT - 84 
Progression free survival 
at 3 years 
3 
41.1% vs 27.5%, favouring CS 
NNT - 8 
Tumour downstaging 6 
49.9% vs 37.5% for T0-2 favouring CS 
NNT - 9 
R0 resection rate 8 75.2% vs 69.9%, favouring CS 
Perioperative mortality 3 5.4% vs 4.6%, equivalent 
Subgroup analyses n/a 
Effect on overall survival higher for T3 
and T4 lesions 
Effects higher in Western studies 
Monotherapy inferior to multiple drug 
regimens 
IV route better than others 
Table 3. Conclusions from the meta-analysis of neoadjuvant chemotherapy for gastric cancer 
by Li et al 2010. CS – neoadjuvant, S – surgery only, n/a not applicable, NNT – numbers 
needed to treat, IV – intravenous administration. 
4. Neoadjuvant chemo-radiotherapy for oesophageal cancer 
Neoadjuvant chemo-radiotherapy aims to downstage tumours preoperatively and reduce 
the risk of both local and distant metastatic recurrence. There has been great interest in this 
area with nine randomised control trials comparing overall survival between patients 
receiving neoadjuvant chemo-radiotherapy plus surgery (CRTS) and surgery alone (S) in 
oesophageal cancer patients. Table 6 summarises the treatment regimens while Table 7 
shows the overall mortality estimates for each trial. 
As shown in Tables 4 the numbers of patients taking part in each chemo-radiotherapy trial is 
relatively small. Treatment regimens also differ with radiation doses ranging from 20 to 50.4 
Gy given either concurrently with the chemotherapy or sequentially which would reduce 
radiosensatisation of the tumour. The type of chemotherapeutic agents administered also 
varies. However, in the majority of trials, this is in the form of cisplatin (20-100mg/m2) and 
5-fluorouracil (300-1000mg/m2). 
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Trial 
Cell 
Type 
CRTS 
n 
S 
n 
CRT 
Treatment 
Sequential 
or Concurent 
radiotherapy
Hazard 
Ratio 
(95% CI) 
Nygaard et al 
1992 
SCC 53 25 
Cisplatin, 
Bleomycin 
& 35Gy
Sequential 
0.76 (0.45-
1.28) 
Apinop et al 1994 SCC 35 34 
Cisplatin, 
5FU & 
40Gy
Concurrent 
0.80 (0.48-
1.34) 
Le Prise et al 1994 SCC 41 41 
Cisplatin, 
5FU & 
20Gy
Sequential 
0.85 (0.50-
1.46) 
Walsh et al 1996 Adeno 48 50 
Cisplatin, 
5FU & 
40Gy
Concurrent 
0.58 (0.38-
0.88) 
Bosset et al 1997 SCC 148 148 
Cisplatin & 
37 Gy
Sequential 
0.96 (0.73-
1.27) 
Urba et al 2001 
Adeno 
& SCC
50 50 
Cisplatin, 
5FU & 
45Gy
Concurrent 
0.74 (0.48-
1.12) 
Lee et al 2004 SCC 51 50 
Cisplatin, 
5FU & 
45.6Gy
Concurrent 
0.88 (0.48-
1.62) 
Burmeister et al 
2005 
Adeno 
& SCC
128 128 
Cisplatin, 
5FU & 
35Gy
Concurrent 
0.94 (0.70-
1.26) 
Tepper et al 2008 
Adeno 
& SCC
30 26 
Cisplatin, 
5FU & 
50.4Gy
Concurrent 
0.40 (0.18-
0.87) 
Walsh et al 
1995,unpublished
SCC 29 32 
Cisplatin, 
5FU & 
40Gy
Concurrent 
0.74 (0.46-
1.18) 
Total  623 586   
0.81 (0.70-
0.93) 
Table 4. Summary of treatment given in chemo-radiotherapy trials & overall mortality 
estimates for neoadjuvant chemo-radiotherapy compared to surgery alone. SCC- Squamous 
cell carcinoma, Adeno - Adenocarcinoma, CRTS - Chemo-radiotherapy+Surgery, S -Surgery 
alone, CRT – Chemo-radiotherapy 
Although most of the trials suggest there is benefit from giving preoperative chemo-
radiotherapy, only two show a significant benefit in terms of overall mortality when 
compared to surgery alone. These studies are those by Walsh et al 1996 (HR 0.58;95% CI 
0.38-0.88) who only enrolled adenocarcinoma patients and Tepper et al 2008 (HR 0.40; 95% 
CI 0.18-0.87) who included approximately 25% squamous cell carcinoma patients. 
In order to shed more light on the effect of chemo-radiotherapy two recent meta-analyses 
have been published Gebski et al (2007) and Jin et al (2009). 
Gebski et al using the pooled data showed that there was a relative reduction in mortality 
for patients receiving neoadjuvant chemo-radiotherapy (HR 0.81; 95% CI 0.70–0.93; p=0.002) 
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and that there was no evidence of heterogeneity between the trials or any temporal effect. 
Gebski et al. went on to look at the survival benefit of chemo-radiotherapy for the different 
tumour cell types. Patients with adenocarcinoma were shown to benefit (HR 0.75; 95% CI 
0.59–0.95; p=0.02) while those with squamous cell carcinoma receiving sequential 
radiotherapy gained no survival advantage (HR 0.9; 95% CI 0.72-1.03; p=0.18.) However, 
when radiotherapy was administered concurrently a significant survival benefit was seen in 
squamous cell carcinoma patients (HR 0.76; 95%CI 0.59-0.98; p=0.04).  
Jin et al 2009 using the same data as Gebski et al (plus the addition of a trial by Natsugoe et al 
2006 containing 55 patients) also concluded that oesophageal cancer patients gain a survival 
benefit from receiving neoadjuvant chemotherapy Odds Ratio (OR) 1.78 (95% CI 1.20-2.66,  
p = 0.004) for 3 year survival. The paper goes on to state that there is no survival benefit 
from chemo-radiotherapy for those patients with squamous cell carcinoma (OR 1.34; 95% CI 
0.98-1.82; p = 0.07) for 3-year survival implying only adenocarcinoma patients benefit. This 
should be treated with caution as odds ratios have been superseded by hazard ratios as a more 
reliable method of survival analysis. Furthermore, Jin et al 2009 suggest that the p value of 0.04 
for the hazard ratio relating to concurrent chemo-radiotherapy providing survival benefit for 
SCC patients in Gebski et al meta-analysis is not significant. However, an important point 
made by Jin et al is that the post-operative mortality of chemo-radiotherapy patients is 
significantly higher than those receiving surgery alone (OR: 1.68, 95% CI: 1.03-2.73, p = 0.04). 
This point was also noted in the meta-analysis by Fiorica et al (2004). 
5. Conclusion 
To date, no randomised control trial has shown any survival benefit from neoadjuvant 
radiotherapy in the treatment of resectable oesophageal cancer. A number of trials have 
suggested preoperative chemotherapy could improve survival (Roth et al 1988, Law et al 
1997, Ancona et al 2001 & MRC 2002) However, only the MRC 2002 and MRC MAGIC trial 
2006 (only 26% of which had lower oesophageal/gastro-oesophageal junction tumours) 
showed a small improvement that was statistically significant. For chemo-radiotherapy, the 
studies by Walsh et al (1996) and Tepper et al (2008) are the only two trials to show a 
significant survival benefit. 
All the trials investigating neoadjuvant chemotherapy or chemo-radiotherapy were small in 
size, often lacking the power necessary to detect small differences between groups. In order 
to detect a small yet worthwhile benefit from these different treatment modalities, data have 
been pooled for meta-analysis. The most comprehensive of these by Gebski et al (2007) 
showed an overall survival benefit from neoadjuvant chemo-radiotherapy of 13% at two 
years and a benefit of 7% at two years from preoperative chemotherapy. When looking at 
histological subtypes; chemo-radiotherapy improved survival for both adenocarcinoma and 
squamous cell carcinoma patients; chemotherapy also improved survival in those with 
adenocarcinoma however, no benefit was shown for patients with squamous cell carcinoma. 
Although chemo-radiotherapy has been shown to provide the greatest survival benefit, it has 
been associated with a higher post-operative mortality (Fiorica et al 2004 & Jin et al 2008). As a 
consequence, clinicians are still divided as to which treatment would be best for their patients. 
In this chapter, the majority of trials discussed have employed cisplatin and 5-FU. However, 
the doses and radiation given to those patients receiving chemoradiotherapy have varied, 
which makes comparisons between trials more difficult. All the randomised control trials 
were designed over a decade ago. Since then, new chemotherapeutic agents have become 
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available and the delivery of radiotherapy has also advanced. In recent years the use of 
taxanes, when given concurrently with radiotherapy in the treatment of non-small cell lung 
cancer, have shown potential (Choy et al 1998, 2000 & Lau 2001). In a phase II trial, Van 
Meerten et al (2006) used Paclitaxel and Carboplatin with concurrent radiotherapy (total 
dose 41.4Gy) in oesophageal cancer patients with encouraging results. The CROSS trial uses 
the same chemo-radiotherapy regime in a phase III randomised control trial comparing 
neoadjuvant chemo-radiotherapy followed by surgery with surgery alone for surgically 
resectable oesophageal adenocarcinoma and squamous cell carcinoma (Van Meijl et al 2008).  
After the encouraging results of both the MRC 2002 and MAGIC trials further investigation of 
neoadjuvant chemotherapy to treat oesophageal cancer in the form of the OE05 trial are on-
going. OE05 is a randomised control trial comparing standard noeadjuvant chemotherapy (2 
cycles of cisplatin + 5FU) with neoadjuvant ECX (4 cycles of Epirubicin, Cisplatin and 
Capecitabine) (OE05 clinical protocol 2008). The results of both trials are keenly awaited. 
The major drawback with chemotherapy and chemo-radiotherapy lies in that both 
treatments are non-specific for the tumour or metastases they are targeting. A significant 
amount of non-malignant tissue is injured by both forms of treatment. In an attempt to fine 
tune the delivery of radiotherapy brachytherapy has been used in the palliative treatment of 
patients with advanced luminal oesophageal cancer. Overall survival at one year was 19.4% 
(Sur et al 1998). More recently, immunotherapy in the form of tumor-infiltrating 
lymphocytes (TILs), tumour vaccines and adoptive T-cell immunotherapy, which 
specifically targets tumour cell surface antigens using a chimeric immune receptor have 
been developed. Specific targeting would reduce damage of non-malignant tissue, could 
have the ability to down stage tumours preoperatively, mop up any residual micro 
metastases following surgery and might be an alternative neoadjuvant treatment in the 
future. A number of small preliminary trials have sown the possible potential of an 
immunotherapy approach however, larger clinical trials are needed.  
In summary neoadjuvant chemotherapy and chemo-radiotherapy have both shown a 
significant benefit to survival of oesophageal cancer patients with resectable disease. 
Chemo-radiotherapy appears more effective, however, is associated with a higher 
postoperative mortality than preoperative chemotherapy. Further large scale randomised 
control trials using new chemotherapeutic agents are on the horizon and new treatments 
such as immunotherapy which have the ability to specifically target only malignant tissue 
may provide further improvement in survival in these patients. 
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